MESO Q3 2021 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-84.2% YoY

Gross Profit

-$18M-933.6% margin

Operating Income

-$26M-1354.2% margin

Net Income

-$27M-1386.0% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-14.4%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$34M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$766M

Total Liabilities

$165M

Stockholders' Equity

$601M

Cash & Equivalents

$158M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$12M	-84.2%
Gross Profit	-$18M	-$10M	-80.2%
Operating Income	-$26M	-$16M	-66.9%
Net Income	-$27M	-$15M	-73.7%